6 research outputs found

    Structure of SALO, a leishmaniasis vaccine candidate from the sand fly <i>Lutzomyia longipalpis</i>

    No full text
    <div><p>Background</p><p>Immunity to the sand fly salivary protein SALO (<b>S</b>alivary <b>A</b>nticomplement of <i>Lutzomyia</i> <b><i>lo</i></b><i>ngipalpis</i>) protected hamsters against <i>Leishmania infantum</i> and <i>L</i>. <i>braziliensis</i> infection and, more recently, a vaccine combination of a genetically modified <i>Leishmania</i> with SALO conferred strong protection against <i>L</i>. <i>donovani</i> infection. Because of the importance of SALO as a potential component of a leishmaniasis vaccine, a plan to produce this recombinant protein for future scale manufacturing as well as knowledge of its structural characteristics are needed to move SALO forward for the clinical path.</p><p>Methodology/Principal findings</p><p>Recombinant SALO was expressed as a soluble secreted protein using <i>Pichia pastoris</i>, rSALO(P), with yields of 1g/L and >99% purity as assessed by SEC-MALS and SDS-PAGE. Unlike its native counterpart, rSALO(P) does not inhibit the classical pathway of complement; however, antibodies to rSALO(P) inhibit the anti-complement activity of sand fly salivary gland homogenate. Immunization with rSALO(P) produces a delayed type hypersensitivity response in C57BL/6 mice, suggesting rSALO(P) lacked anti-complement activity but retained its immunogenicity. The structure of rSALO(P) was solved by S-SAD at Cu-K<sub>alpha</sub> to 1.94 Å and refined to <i>R</i><sub><i>factor</i></sub> 17%. SALO is ~80% helical, has no appreciable structural similarities to any human protein, and has limited structural similarity in the C-terminus to members of insect odorant binding proteins. SALO has three predicted human CD4<sup>+</sup> T cell epitopes on surface exposed helices.</p><p>Conclusions/Significance</p><p>The results indicate that SALO as expressed and purified from <i>P</i>. <i>pastoris</i> is suitable for further scale-up, manufacturing, and testing. SALO has a novel structure, is not similar to any human proteins, is immunogenic in rodents, and does not have the anti-complement activity observed in the native salivary protein which are all important attributes to move this vaccine candidate forward to the clinical path.</p></div

    Antibodies against rSALO(P) block anti-complement activity present in the salivary glands of the sand fly <i>Lutzomyia longipalpis</i> (SGH).

    No full text
    <p>(A) Hemolytic assays using SGH (0.5 salivary gland pairs) in the presence of different dilutions of anti-rSALO(P) antibodies (1:10; 1:100; 1:1000 or 1:10000, in PBS). The data represents the mean ± standard deviation of three independent repetitions (ANOVA and Tukey test). Hemolysis was measured at 414nm. (B) Western blot showing rSALO(P) antibodies recognizing rSALO(P) (rSALO Pichia), native SALO from the salivary gland homogenate of <i>Lutzomyia longipalpis</i> (SGH), and rSALO(H) (rSALO HEK). SDS-PAGE was run under reducing conditions. Pre-immune sera was used as a control.</p

    Comparison of SALO to PdSP15.

    No full text
    <p>(A) Ribbon diagram of a SALO monomer. (B) Ribbon diagram of pdsp15 (C) C-terminus of SALO (grey) superposes well with PdSP15 (aqua marine). (D) The amino acid sequence alignment comparing SALO to PdSP15 generated with <i>ESPript</i>3.0 [<a href="http://www.plosntds.org/article/info:doi/10.1371/journal.pntd.0005374#pntd.0005374.ref036" target="_blank">36</a>] reveals a conserved C-terminal odorant-binding domain. The location of the three predicted T-cell epitopes are shown as black lines. Secondary-structure elements are as follows: α-helices (α), 3<sub>10</sub>-helices (η), β-strands (β) and β-turns (TT). Identical residues are shown on a red background; conserved residues are shown in red; and conserved regions are shown in blue boxes.</p
    corecore